Age-Adjusted Schedules of Venetoclax and Hypomethylating Agents to Treat Extremely Elderly Patients with Acute Myeloid Leukemia
Open Access
- 26 April 2022
- journal article
- research article
- Published by Hindawi Limited in Case Reports in Hematology
- Vol. 2022, 1-6
Abstract
Acute myeloid leukemia (AML) is associated with particularly poor outcomes in the elderly population, in whom the disease is most prevalent. BCL-2 has been identified as an antiapoptotic protein and promotes survival of leukemia stem cells. Recently, the United States FDA has approved venetoclax, a selective oral BCL-2 inhibitor, for use in conjunction with hypomethylating agents (azacitidine or decitabine) or low-dose cytarabine as a first-line treatment option for those AML patients ineligible for standard induction chemotherapy. However, there are nuances and challenges when using this regimen in the extremely elderly AML patients. Given the widespread adoption of this regimen and increasing prevalence of patients who are well into their 80 s, it is important to evaluate and understand how to safely use this regimen in this so-called "extremely elderly " population. We present here 3 case studies involving AML patients > 85 years of age who were treated with venetoclax plus HMA and provide clinical knowledge on how this population should be appropriately managed.Keywords
This publication has 7 references indexed in Scilit:
- Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AMLBlood, 2022
- Azacitidine and Venetoclax in Previously Untreated Acute Myeloid LeukemiaNew England Journal of Medicine, 2020
- Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trialBlood, 2020
- Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II StudyJournal of Clinical Oncology, 2019
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemiaBlood, 2019
- Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic SyndromeBlood, 2018
- Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b studyThe Lancet Oncology, 2018